EMA: First International Workshop on Nanomedicine - NEW DATE!
Market Watch: Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment
Up one levelGround-Breaking Technology Developed by Dr. Edward R. Flynn Requires No Radiation and is 100x More Sensitive Than Existing Diagnostics; Techniques Enable Early Cancer Detection and Precise, Image Guided Cancer Therapies
ALBUQUERQUE, N.M., Feb 25, 2010 (BUSINESS WIRE) -- Manhattan Scientifics Inc. /quotes/comstock/11k!mhtx (MHTX 0.11, 0.00, -2.73%) , a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC. The breakthrough technology focuses on the emerging field of nanomedicine, with an emphasis on the early detection and localization of cancer and other diseases, and providing image-guided therapy for treatment. Financial details of the agreement were not disclosed.
